CD274 and neoplasm: Immune checkpoint inhibitors, including inhibitors of programmed death ligand 1 (PDL1) and its receptor programmed death 1 (PD1), have been most widely used clinically, achieving over‐expected efficacy in a variety of patients with refractory, relapsed tumors.[1] Although immunotherapy has had remarkable results, not all patients will benefit from it,[2] attributed to the inherent temporal, and spatial heterogeneity of PD1/PDL1 expression within the tumor.